Immuneering Corp 8-K

What Happened
Immuneering Corporation (IMRX) filed a Current Report on Form 8‑K on March 6, 2026 to announce its financial results for the quarter and the full year ended December 31, 2025 and to provide operational updates. The full text of the press release containing the earnings and updates is furnished as Exhibit 99.1 to the 8‑K.

Key Details

• Item reported: 2.02 — Results of Operations and Financial Condition (announced Q4 and FY2025 results).
• Filing date: March 6, 2026; reporting period: quarter and full year ended December 31, 2025.
• Press release with the detailed earnings and operational update is attached to the 8‑K as Exhibit 99.1.
• Item 9.01 (Financial Statements and Exhibits) lists the exhibit filing (Exhibit 99.1).

Why It Matters
This 8‑K signals Immuneering has released its quarterly and annual earnings and related operational information; those details (revenue, R&D spending, net loss or income, cash position, program updates) will be found in the attached press release. Retail investors should review Exhibit 99.1 and any subsequent SEC filings for the specific financial figures and management commentary to assess impacts on revenue trends, cash runway, and program milestones.